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Objectives: Studies of neurocognitively elite older adults, termed SuperAgers, have identiﬁed clinical predictors and
neurobiological indicators of resilience against age-related neurocognitive decline. Despite rising rates of older persons
living with HIV (PLWH), SuperAging (SA) in PLWH remains undeﬁned. We aimed to establish neuropsychological criteria for SA in PLWH and examined clinically relevant correlates of SA. Methods: 734 PLWH and 123 HIV-uninfected
participants between 50 and 64 years of age underwent neuropsychological and neuromedical evaluations. SA was
deﬁned as demographically corrected (i.e., sex, race/ethnicity, education) global neurocognitive performance within normal range for 25-year-olds. Remaining participants were labeled cognitively normal (CN) or impaired (CI) based on
actual age. Chi-square and analysis of variance tests examined HIV group differences on neurocognitive status and demographics. Within PLWH, neurocognitive status differences were tested on HIV disease characteristics, medical comorbidities, and everyday functioning. Multinomial logistic regression explored independent predictors of neurocognitive status.
Results: Neurocognitive status rates and demographic characteristics differed between PLWH (SA = 17%; CN = 38%;
CI = 45%) and HIV-uninfected participants (SA = 35%; CN = 55%; CI = 11%). In PLWH, neurocognitive groups were
comparable on demographic and HIV disease characteristics. Younger age, higher verbal IQ, absence of diabetes, fewer
depressive symptoms, and lifetime cannabis use disorder increased likelihood of SA. SA reported increased independence
in everyday functioning, employment, and health-related quality of life than non-SA. Conclusions: Despite combined
neurological risk of aging and HIV, youthful neurocognitive performance is possible for older PLWH. SA relates to
improved real-world functioning and may be better explained by cognitive reserve and maintenance of cardiometabolic
and mental health than HIV disease severity. Future research investigating biomarker and lifestyle (e.g., physical activity)
correlates of SA may help identify modiﬁable neuroprotective factors against HIV-related neurobiological aging. (JINS,
2019, 25, 507–519)
Keywords: Neuropsychology, Cognitive reserve, Cognitive decline, Diabetes, Cannabis, Acquired Immunodeﬁciency
Syndrome

Correspondence and reprint requests to: David J. Moore, University of
California, San Diego, HIV Neurobehavioral Research Program, 220
Dickinson Street, Suite B, MC8231, San Diego, CA 92103-8231.
E-mail: djmoore@ucsd.edu

INTRODUCTION
Antiretroviral therapy (ART) has facilitated increased life
expectancy for people living with HIV (PLWH; Wing, 2016).
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In 2014, 45% of PLWH in the United States were over the
age of 50 (Centers for Disease Control and Prevention, 2018)
and this proportion is expected to increase (Smit et al., 2015).
HIV-associated neurocognitive disorder (HAND) affects
approximately half of PLWH (Heaton et al., 2010; Norman
et al., 2011; Saloner & Cysique, 2017), and older PLWH are
at three times higher risk for HAND compared to younger
PLWH (Valcour et al., 2004). Furthermore, there is evidence
to suggest that HIV accelerates and accentuates neurocognitive aging (Pathai, Bajillan, Landay, & High, 2014; Sheppard
et al., 2017). Older PLWH are at increased risk for functional
decline (Thames et al., 2011; Vance, Fazeli, & Gakumo,
2013), which is not only costly, but also negatively affects
quality of life (Morgan et al., 2012). Identifying factors that
promote successful cognitive aging with HIV and developing
interventions to sustain or enhance them may avoid or reverse
the adverse effects of aging.
While deﬁnitions of successful cognitive aging in PLWH
differ slightly, all deﬁnitions require individuals to be neurocognitively unimpaired and functionally independent
(Malaspina et al., 2011; Moore et al., 2017). Successful
cognitive aging rates in older PLWH range from 19–32%,
and translates into real-world beneﬁts, including greater
success in managing medication and medical appointments,
less decline in activities of daily living, and better psychological health and health-related quality of life (HRQoL)
(Malaspina et al., 2011; Moore et al., 2017, 2014). Given that the
neuropsychological criteria for successful cognitive aging solely
requires the absence of neurocognitive impairment, taking into
consideration age, there likely remains considerable heterogeneity in neurocognitive performance (e.g., low average to
superior) among the successful cognitive aging group.
Thus, distinguishing older PLWH with superior neurocognitive
abilities from those with average neurocognitive abilities may
explain additional variance in everyday functioning outcomes.
Older adults with preserved cognition appear to resist
“normal” age-related decline. The term SuperAger refers to
older adults that perform equivalently to young or middleaged adults on episodic memory tests (Harrison, Maass,
Baker, & Jagust, 2018; Rogalski et al., 2013; Sun et al.,
2016). Alternatively, others have researched “SuperNormals” or “Optimal Memory Performers” – older adults
who demonstrate above-average episodic memory performance in comparison to average older adults (Dekhtyar et al.,
2017; Lin et al., 2017; Mapstone et al., 2017; Wang et al.,
2019). Both deﬁnitions provide evidence that older adults
with superior memory perform better on other cognitive
domains, particularly executive functioning (Dekhtyar et al.,
2017; Gefen et al., 2015) and processing speed (Dekhtyar
et al., 2017; Harrison et al., 2018).
Additionally, SuperAgers have larger volumes of the cerebral
cortex, hippocampus, and cingulate cortex (Dekhtyar et al.,
2017; Harrison et al., 2018; Lin et al., 2017; Rogalski et al.,
2013; Sun et al., 2016; Wang et al., 2019) as well as slower rates
of cortical atrophy (Cook et al., 2017). Furthermore, SuperAgers display lower levels of biomarkers of neurodegeneration
such as oxidative stress (Mapstone et al., 2017), inﬂammation
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(Bott et al., 2017), and amyloid (Lin et al., 2017; Rogalski et al.,
2013) and tau deposition (Gefen et al., 2015).
Despite not having a gold-standard deﬁnition of SuperAging (SA) or preserved cognition, commonalities exist
among the deﬁnitions. Most studies have classiﬁed SuperAgers based on superior memory performance alone and only
required either average age-adjusted performance for a few
other neuropsychological measures (Harrison et al., 2018;
Rogalski et al., 2013). Some have required that they be
otherwise neurocognitively normal (Dekhtyar et al., 2017;
Lin et al., 2017). Thus, SA studies predominantly focus on
superior memory performance rather than superior global
neurocognitive performance.
The majority of these studies, which consist of primarily
septua- and octogenarians, require SuperAgers to perform
equivalent to or better than those in their mid-50s; however,
most neurocognitive abilities peak in the mid-20s and then
begin to decline (Hartshorne & Germine, 2015; Heaton,
Taylor, & Manly, 2003; Salthouse, 2003, 2009). Although
SA is typically evaluated in healthy adults who are at least
60 years old, the aging population of PLWH is younger with
50 years old serving as a cutoff for deﬁning a medically
advanced age (Blanco et al., 2012). Nevertheless, neurocognitive aging studies have demonstrated substantial interindividual variability in neurocognition for healthy adult cohorts
below the age of 60 (Lachman, Teshale, & Agrigoroaei, 2015;
Martin & Zimprich, 2005; Schaie & Willis, 2010). Importantly,
this heterogeneity in neurocognition tracks with variation in
biopsychosocial factors such that high neurocognitive performance correlates with high cognitive reserve and low comorbidity burden (Anstey, Sargent-Cox, Garde, Cherbuin, &
Butterworth, 2014; Ferreira et al., 2017).
While current deﬁnitions of SA may be appropriate for
studying healthy older adults resistant to the clinical expressions of biological aging and Alzheimer’s disease, SA criteria
should be tailored for study in older PLWH who are younger
and at greater risk for multi-domain neurocognitive decline
rather than focal memory deﬁcits. Thus, we aimed to:
(1) establish neuropsychological criteria for neurocognitive
SA in PLWH; (2) identify clinical predictors of SA in PLWH;
(3) assess the everyday functioning correlates of SA status.

METHODS
Participants
Participants included 734 PLWH and 123 HIV-uninfected
controls aged 50–64 years. A total of 340 PLWH were
enrolled in the NIH-funded CNS HIV Anti-Retroviral Therapy
Effects Research (CHARTER) study, consisting of six
participating university centers: Johns Hopkins University
(Baltimore, MD; n = 51); Mt. Sinai School of Medicine (New
York, NY; n = 92); University of California at San Diego
(San Diego, CA; n = 32); University of Texas Medical
Branch (Galveston, TX; n = 73); University of Washington
(Seattle, WA; n = 38); and Washington University (St. Louis,
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MO; n = 54). The remaining 394 PLWH and 123 HIVuninfected participants were enrolled in other NIH-funded
research studies at the University of California, San Diego’s
HIV Neurobehavioral Research Program (HNRP). All participant visits for the present study took place between 2002
and 2017. All studies were approved by local Human Subjects Protection Committees, and all participants provided
written informed consent. All PLWH were required to have
≥5 years of estimated duration of HIV disease to be considered for inclusion.
Exclusion criteria were: (1) diagnosis of psychotic or mood
disorder with psychotic features, neurological, or medical
condition that may impair neurocognitive functioning, such
as traumatic brain injury, stroke, epilepsy, or advanced liver
disease; (2) low verbal IQ of <70 as estimated by the reading
subtest of the Wide Range Achievement Test (WRAT;
Wilkinson & Robertson, 2006); or (3) evidence of intoxication by illicit drugs (except marijuana) or Breathalyzer test
for alcohol on the day of testing by positive urine toxicology.

Table 1. Neurocognitive tests administered by domain
Domain
Verbal ﬂuency
Attention/working
memory

Processing speed

Executive
functioning

Learning

Procedures
Neurocognitive assessment
Participants were classiﬁed as SA based on their performance
on a comprehensive and standardized battery of neurocognitive tests, which has been described in detail elsewhere
(Carey et al., 2004; Heaton et al., 2010) (Table 1). Brieﬂy, the
battery covers seven neurocognitive domains commonly
impacted in HIV-infected persons: verbal ﬂuency, executive
functioning, processing speed, learning, delayed recall,
attention/working memory, and motor skills (Heaton et al.,
2010). Since some participants had been exposed to the test
battery at prior research visits, raw scores for each test were
converted to practice effect-adjusted scaled scores (M = 10;
SD = 3; Heaton et al., 2001). These demographically uncorrected scaled scores were converted to T scores (M = 50;
SD = 10) that corrected for the effects of age, education, sex,
and race/ethnicity on neurocognition (Heaton, Miller, Taylor,
& Grant, 2004; Heaton et al., 2003; Norman et al., 2011).
To generate variables that reﬂect maximum neurocognitive
performance at a younger age, a second set of adjusted T
scores were computed in which the age of 25, instead of
actual age, was entered into the demographic correction formulas along with actual education, sex, and race/ethnicity.
These scores, referred to as “peak-age” T scores, consequently compare an individual’s neurocognitive performance
to normative standards for 25-year-olds of the same education, sex, and race/ethnicity (Heaton, Miller, et al., 2004;
Heaton et al., 2003; Norman et al., 2011). Both the actual-age
and peak-age T scores for each measure were averaged to
compute global and domain-speciﬁc T scores within each
cognitive ability area. T scores were converted to actual-age
and peak-age domain-speciﬁc deﬁcit scores (DDS) that give
differential weight to impaired, as opposed to normal scores,
on a scale ranging from 0 (T ≥ 40; normal) to 5 (T < 20;
severe impairment). DDS were then averaged to generate

Delayed recall

Motor skills

Test
Category Fluencya
Letter Fluencya
Paced Auditory Serial Addition Taska
WAIS–III Letter-Number Sequencingb,c
WMS-III Spatial Spanb,c
WAIS–III Digit Symbola
WAIS–III Symbol Searcha
Trail Making Test Aa
Stroop Color & Word Test Color Scoreb,d
Wisconsin Card Sorting Test-64
Perseverative Errorsa
Trail Making Test Ba
Stroop Color & Word Test Interference
Scoreb,d
Halstead Category Testb
Hopkins Verbal Learning Test–Revised
Total Learninga
Brief Visuospatial Memory Test–Revised
Total Learninga
Story Memory Test Learningb,e
Figure Memory Test Learningb,e
Hopkins Verbal Learning Test–Revised)
Delayed Recalla
Brief Visuospatial Memory Test–Revised
Delayed Recalla
Story Memory Test Delayed Recallb,e
Figure Memory Test Delayed Recallb,e
Grooved Pegboard Test- Dominant Handa
Grooved Pegboard Test- Non-dominant
Handa

Note.
a
Core test administered across all studies with less than 5% missing data in
the present sample.
b
Supplemental test administered in select studies.
c
Each study participant completed WAIS-III Letter-Number Sequencing
(n = 525) and/or WMS-III Spatial Span (n = 224).
d
n = 308.
e
Hopkins Verbal Learning Test-Revised and Brief Visuospatial Memory
Test-Revised data were not used for learning and delayed recall domain
scores for participants who also completed Story Memory Test and Figure
Memory Test (n = 138) data.
Bolded items have the greatest inﬂuence on global neurocognitive performance scores.

an actual-age and peak-age global deﬁcit score (GDS).
Consistent with prior studies, the presence of global impairment was deﬁned by GDS ≥ 0.5 and domain-speciﬁc
impairment by DDS > 0.5 (Blackstone et al., 2012; Carey
et al., 2004).

SuperAging criteria
To estimate intact and peak neurocognitive functioning, SA
status was operationally deﬁned as: (1) peak-age GDS < 0.5;
and (2) actual-age DDS ≤ 0.5 for all seven neurocognitive
domains. Participants that did not meet SA criteria were
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classiﬁed as either cognitively normal (CN) or cognitively
impaired (CI) using the standard actual-age GDS impairment
cut-point of ≥ 0.5 (Figure 1).

Neuromedical and laboratory assessment
All participants underwent a comprehensive neuromedical
assessment, including a medical history that included medications, Centers for Disease Control staging, and blood draw.
HIV infection was diagnosed by enzyme-linked immunosorbent assay with Western blot conﬁrmation. Routine clinical chemistry panels, complete blood counts, rapid plasma
reagin, hepatitis C virus antibody, and CD4 + T cells (ﬂow
cytometry) were performed at each site’s Clinical Laboratory
Improvement Amendments (CLIA)–certiﬁed, or CLIA
equivalent, medical center laboratory. Levels of HIV viral
load in plasma were measured using reverse transcriptasepolymerase chain reaction (Amplicor, Roche Diagnostics,
Indianapolis, IN, with a lower limit of quantitation 50 copies/
mL).

Psychiatric assessment
678 PLWH had available data from the Composite International Diagnostic Interview (CIDI), a fully structured,
computer-based interview, to determine DSM-IV diagnoses
for current and lifetime mood and substance use disorders.
(World Health Organization, 1998). Additionally, a subset of
PLWH (n = 712) completed the Beck Depression InventoryII (BDI-II; Beck, Steer, & Brown, 1996) to assess current
symptoms of depressed mood.

Everyday functioning and quality of life assessment
Instrumental activities of daily living (IADL) dependence
was assessed using a revised version of the Lawton and
Brody (1969) self-report measure of everyday functioning
(Heaton, Marcotte, et al., 2004; Woods et al., 2008), in which
participants rated current abilities compared to previous
abilities across 13 everyday functioning domains. Two outcome variables were generated: (1) A continuous variable of
the number of declines in IADL; and (2) a dichotomous
variable for IADL dependence, deﬁned as ≥2 declines at least
partially attributable to cognitive problems.
The Patient’s Assessment of Own Functioning Inventory
(PAOFI) is a 33-item self-report measure used to measure
perceived cognitive symptoms in everyday life (Chelune,
Heaton, & Lehman, 1986). Items endorsed as fairly often or

Fig. 1. Neurocognitive status criteria. SuperAging was
operationalized as a peak-age global deﬁcit score within normal
limits (i.e., less than 0.5) and normal performance on all seven
actual-age deﬁcit scores (i.e., less or equal than 0.5).
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greater are considered clinically signiﬁcant cognitive symptoms. A continuous variable for total number of clinically
signiﬁcant everyday cognitive symptoms and a dichotomous
variable for employment status (i.e., employed/unemployed)
were examined as outcome variables.
A subset of PLWH (n = 490) completed the Medical
Outcome Study 36 Item Short-Form version 1.0 (MOSSF-36), which assesses HRQoL. The reliability and validity
of the MOS-SF-36 has been extensively documented in
PLWH (Henderson et al., 2010; Wu, Revicki, Jacobson, &
Malitz, 1997). For this study, the physical and mental health
composite scores were examined as primary outcome
variables.

Statistical Analyses
HIV group differences on neurocognitive status and demographics were examined using analyses of variance or
Kruskal-Wallis tests for continuous variables and chi-square
statistics for categorical variables. For the PLWH group only,
the same statistical tests examined neurocognitive status
group differences on demographics, HIV disease severity,
medical and psychiatric characteristics, and everyday functioning outcomes. All pair-wise post hoc comparisons (SA
vs. CN, SA vs. CI, and CN vs. CI) were conducted for any
variable with at least an omnibus trend-level (i.e., p < .10)
difference across neurocognitive status groups. To control for
multiple comparisons and limit Type I error, Tukey’s honest
signiﬁcant difference (HSD) tests were conducted for continuous variables and Bonferroni-corrections were applied to
chi-square tests (MacDonald & Gardner, 2000). Cohen’s d
statistics are presented for estimates of effect size for pairwise comparisons. All group difference analyses were performed using JMP Pro version 12.0.1 (JMP®, Version
< 12.0.1 > , SAS Institute Inc., Cary, NC, 1989–2007).
Next, any variable that displayed at least an omnibus trendlevel difference was entered into a multinomial regression to
determine the degree to which demographic and clinical characteristics segregate according to neurocognitive status. Race/
ethnicity, sex, and education were not included in the model
because the criteria for establishing neurocognitive status
already adjusted for these factors. Actual age, however, was
included in the model since the SA criteria adjusted each participant’s performance at peak age (i.e., 25) instead of actual age.
To determine the impact of age on global functioning
within each neurocognitive status group (PLWH only), we
conducted Pearson partial correlations between age and
demographically uncorrected global scaled scores stratiﬁed
by group, co-varying for education, sex, and race/ethnicity.
We calculated standardized Pearson partial r values that serve
as effect sizes to enhance comparability and interpretability
of the relationship between age and global neurocognitive
performance across the neurocognitive status groups. Statistical differences in the magnitude of the Pearson partial correlations were compared using Fisher’s r-to-z transformations
for independent correlations. Multinomial regression and
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Pearson’s partial correlations were performed using SPSS 24
(SPSS Inc., Chicago, IL).

RESULTS
SuperAging Prevalence
Of the 734 PLWH, 124 (17%) met criteria for SA. Of the
remaining 610 non-SA participants, 279 (38%) were CN and
331 (45%) were CI. Figure 2 displays differences in actualage T and peak-age T scores within and across SA and CN
PLWH with Cohen’s d effect size estimates for actual-age T
scores. The prevalence of SA and CN were signiﬁcantly
higher, and prevalence of CI was signiﬁcantly lower, in the
HIV-uninfected group (χ 2 = 63.7; p < .0001). Of the 123
HIV-uninfected participants, 43 (35%) were SA, 67 (55%)
were CN, and 13 (11%) were CI.

Demographics
Table 2 displays PLWH neurocognitive status group differences in demographic, clinical, and neuromedical variables.
Only percent non-Hispanic white differed signiﬁcantly
among demographic factors. Although the CN group exhibited the lowest proportion of non-Hispanic white, no signiﬁcant pairwise differences were found. SA individuals
were on average a year younger than their CN and CI counterparts and this difference approached signiﬁcance, but this
did not result in signiﬁcant pairwise differences. Although
groups did not differ with respect to education, SA displayed
signiﬁcantly higher WRAT scores than CN (d = 0.43) and CI
(d = 0.61) participants.

Compared to PLWH, the HIV-uninfected comparison group
had signiﬁcantly higher rates of non-Hispanic white participants (81% vs. 58%; p < .0001), females (38% vs. 16%;
p < .0001), mean years of education (14.4 vs. 13.6; p < .001),
and higher mean WRAT scores (106 vs. 98; p < .0001). By
design, the HIV-uninfected group did not signiﬁcantly differ
from PLWH in mean age (55.5 vs. 55.1; p = .87).

HIV Disease Characteristics
A stair-step pattern of indicators of HIV disease severity was
commonly observed such that SA displayed the lowest
amount of HIV disease burden followed by CN then CI
individuals. Although this stair-step pattern occurred for
history of AIDS diagnosis, detectable plasma HIV, current
CD4 count, and nadir CD4 < 200; only omnibus group differences in current CD4 < 200 were signiﬁcant. Post hoc
comparisons indicated that the SA group had signiﬁcantly
lower rates of participants with current CD4 < 200 than the
CI group. In the full sample, participants with current
CD4 < 200 were more likely to be off ART (19.6%) compared to those with current CD4 ≥ 200 (9.8%; χ 2 = 6.7;
p = .01). No noteworthy group differences were found for
estimated duration of HIV disease or receipt of ART.

Medical Comorbidities
Examination of medical comorbidities revealed signiﬁcant
group differences for rates of hepatitis C virus (HCV) seropositivity and diabetes. Post hoc comparisons indicated that
SA had signiﬁcantly lower rates of HCV than the CN group
and lower rates of diabetes than both the CN and CI groups.
No signiﬁcant group differences were found for other

Fig. 2. SuperAger (SA) versus cognitively normal (CN) differences in neurocognitive performance. Cohen’s d effect size estimates reﬂect
differences in actual-age T scores.
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Table 2. Demographic and clinical characteristics by neurocognitive status in people living with HIV

Variable
Demographics
Age (years)b
Gender (male)
Race/ethnicity (non-Hispanic white)
Cognitive reserve
Education (years)
Estimated premorbid verbal IQ (WRAT)
HIV disease characteristics
History of AIDS
Detectable virusc
Current CD4 count
Current CD4 < 200
Nadir CD4 count
Nadir CD4 < 200
Years of known HIV-infection
Mean (SD)
Min - Max
On ART
Medical comorbidities
Hypertension
Hyperlipidemia
BMI
Diabetes
HCV

SA
(n = 124)

CN
(n = 279)

CI
(n = 331)

p

54.3 (3.97)
107 (86.3)
79 (63.7)

55.2 (3.91)
235 (84.2)
142 (50.9)

55.3 (4.08)
276 (83.4)
203 (61.3)

.06
.75
.01

13.4 (2.58)
103.5 (11.82)

13.4 (2.64)
98.1 (13.32)

13.8 (2.69)
96 (12.83)

.14
<.001

90 (72.6)
27 (21.8)
507 [367 – 700]
9 (7.3)
112 [18 – 258]
79 (63.7)

211 (75.6)
71 (25.5)
491 [333 – 691]
31 (11.1)
96 [19 – 225]
196 (70.3)

259 (78.3)
101 (30.5)
488 [275 – 674]
52 (15.7)
97 [21 – 209]
236 (71.3)

.43
.13
.16
.03
.72
.29

18 (6.27)
5.6–31.1
107 (86.3)

17.9 (6.6)
5.4–31.0
249 (89.3)

17.7 (6.54)
5.2–33.7
297 (89.7)

.90
—
.59

48 (38.7)
42 (33.9)
26.5 (5.14)
12 (9.7)
37 (29.8)

124 (44.4)
90 (32.3)
26.6 (5.03)
56 (20.1)
119 (42.7)

148 (44.7)
108 (32.6)
26 (5.08)
62 (18.7)
124 (37.5)

.48
.95
.31
.02
.05

Pair-wise comparisonsa

SA > CN, CI

SA < CI

SA < CN, CI
SA < CN

Note. Values are presented as mean (SD), median [interquartile range], or N (%). WRAT = WRAT, reading subtest version 3 or 4. BMI = body mass index.
a
Pair-wise comparisons were examined using Tukey’s HSD (α = 0.05) for continuous outcomes and Bonferroni-adjustments (α = 0.05/3 = 0.0167) for
dichotomous outcomes.
b
Range of study sample restricted to 50–64 years for each neurocognitive status group.
c
Deﬁned as >50 copies/mL.

markers of metabolic syndrome (i.e., hypertension, hyperlipidemia, body mass index).

Psychiatric and Substance Use Characteristics
Signiﬁcant group differences were observed for rates of
lifetime cannabis use disorder and cocaine use disorder. SA
had signiﬁcantly higher rates of cannabis use disorder than CI
individuals and CN individuals displayed higher rates of
cocaine use disorder than the CI group (Table 3). Although
lifetime and current diagnoses of major depressive disorder
(MDD) did not differ across groups, SA endorsed signiﬁcantly fewer depressive symptoms on the BDI-II than
both the CN (d = −0.35) and CI (d = −0.46) groups.

Multinomial Regression Predicting Neurocognitive
Status
A multinomial logistic regression was performed with the
three neurocognitive groups in PLWH as the dependent
variable. Predictors were all outcome variables from Tables 2
and 3 with a trend-level omnibus effect (excluding race/ethnicity, i.e., age, WRAT, current CD4 < 200, HCV, diabetes,
cannabis use disorder, and BDI-II). Based on available data,
the sample size for this model included 113 SA, 259 CN, and

287 CI participants. Overall, the model was signiﬁcant
(χ 2 (14,659) = 83.73; p < .001; Nagelkerke pseudo-R2 =
0.137). Likelihood ratio tests indicated that older age, lower
WRAT scores, diagnosis of diabetes, and higher BDI-II
scores all increased the likelihood of classiﬁcation as either
CN or CI compared to SA (Table 4). Furthermore, a lifetime
diagnosis of cannabis use disorder decreased the likelihood
of classiﬁcation as CI compared to SA.
To focus on a clinically relevant subgroup, we reran the
multinomial logistic regression among participants with
undetectable levels of HIV plasma RNA. Of the 535 participants with an undetectable viral load, 97 (18%) were SA, 208
(39%) were CN, and 230 (43%) were CI. Age, WRAT, BDIII, and diagnosis of lifetime cannabis use disorder remained
signiﬁcant predictors of neurocognitive status in this virally
suppressed subgroup. Although diabetes increased likelihood
of CN (odds ratio [OR] = 1.74; p = .13) or CI (OR = 1.63;
p = .19) compared to SA, these associations were no longer
statistically signiﬁcant.

Age and Global Performance Relationship by
Neurocognitive Status
To examine the relationship between age and global neurocognitive performance within each neurocognitive status
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Table 3. Neuropsychiatric characteristics by neurocognitive status in people living with HIV

Variable
Lifetime substance use disorders
Alcohol
Cannabis
Cocaine
Methamphetamine
Opioid
Depression
Lifetime MDD
Current MDD (n = 651)
BDI-II (n = 714)

SA
(n = 119)

CN
(n = 264)

CI
(n = 295)

p

72 (60.5)
48 (40.3)
46 (38.7)
31 (26.1)
15 (12.6)

145 (54.9)
91 (34.5)
114 (43.2)
57 (21.6)
43 (16.3)

164 (55.6)
76 (25.8)
96 (32.5)
70 (23.7)
52 (17.6)

.57
.01
.03
.62
.44

66 (55.5)
12 (10.4)
8.7 (8.06)

160 (60.6)
30 (11.6)
11.9 (10.33)

182 (61.7)
34 (12.2)
13.0 (10.36)

.50
.88
<.001

Pair-wise comparisonsa

SA > CI
CN > CI

SA < CN, CI

Note. Values are presented as mean (SD) or N (%). BDI-II = BDI-II total score.
a
Pair-wise comparisons were examined using Tukey’s HSD. (α = 0.05) for BDI-II and Bonferroni-adjustment (α = 0.05/3 = 0.0167) for diagnosis variables.

Table 4. Multinomial logistic regression predicting neurocognitive status in people living with HIV
Outcome: Classiﬁcation as CN (reference: SA)

Outcome: Classiﬁcation as CI (reference: SA)

Predictor

OR

95% CI

p

Predictor

OR

95% CI

p

Age
WRAT
CD4 < 200
HCV
Diabetes
Cannabis
BDI-II

1.10
0.96
1.40
1.32
2.23
0.74
1.04

[1.03, 1.17]
[0.94, 0.98]
[0.60, 3.26]
[0.80, 2.18]
[1.11, 4.47]
[0.46, 1.20]
[1.02, 1.07]

<.001
<.001
.63
.28
.02
.22
<.001

Age
WRAT
CD4 <200
HCV
Diabetes
Cannabis
BDI-II

1.11
0.95
1.98
0.97
2.14
0.46
1.06

[1.05, 1.19]
[0.93, 0.97]
[0.86, 4.51]
[0.59, 1.62]
[1.06, 4.33]
[0.28, 0.75]
[1.03, 1.09]

.001
<.001
.11
.92
.03
.002
<.001

95% CI = 95% conﬁdence interval; WRAT = WRAT, reading subtest version 3 or 4; Cannabis = lifetime cannabis use disorder; BDI-II = BDI-II total score.

group in PLWH, we performed Pearson’s partial correlations
between age and demographically-uncorrected global scaled
scores, co-varying for education, sex, and race/ethnicity. Age
negatively correlated with lower global scaled scores within
the CN (partial r = −.24; p < .001) and CI (partial r = −.15;
p < .001) groups. However, age did not signiﬁcantly relate to
global scaled scores among the SA group (partial r = −.11;
p = .24). Despite this lack of signiﬁcance, comparison of
Fisher’s r-to-z transformed correlations indicated that the
effect size of age on global scaled scores in SA did not signiﬁcantly differ from the effect sizes of age on global scaled
scores in CN (z = 1.23; p = .22) and CI (z = .38; p = .70).
Similarly, the magnitude of the relationship between age and
global scaled scores did not differ between CN and CI
(z = −1.15; p = .25).

Everyday Functioning and HRQoL Correlates of
Neurocognitive Status
A stair-step pattern was observed for most outcomes from the
PAOFI, IADL, and MOS-SF-36 measures, with SA individuals endorsing the most favorable everyday functioning and
HRQoL outcomes followed by CN then CI participants. SA

individuals endorsed signiﬁcantly fewer cognitive symptoms
on the PAOFI than CN (d = −0.34; p < .001) and CI participants (d = −0.64; p < .0001) and fewer declines in IADLs
than either CN (d = −0.42; p < .01) or CI participants
(d = −0.70; p < .0001). The CN group also reported signiﬁcantly fewer cognitive symptoms (d = -0.30; p < .05) and
IADL declines (d = −0.33; p < .001) than the CI group. Figure 3 displays similar group differences on rates of unemployment and IADL dependence as well as the MOS-SF-36
physical and mental HRQoL composite scores.

DISCUSSION
The emerging concept of neurocognitive SA has produced
invaluable insights into age-related neurocognitive phenotypes and has undermined the widely-held assumption that
age-related neurocognitive deterioration is inevitable. However, the prospect of maintaining intact neurocognitive
capacities throughout the lifespan is highly daunting for
PLWH. In our study sample with 17% meeting criteria for
SA, we demonstrate that youthful neurocognitive performance is possible for older PLWH. Our ﬁndings suggest that
SA status is independently related to diverse factors that
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Fig. 3. Everyday functioning and HRQoL by neurocognitive status. Risk ratio (RR) estimates represent the reduction in risk of IADL
dependence or unemployment for each pair-wise comparison. Cohen’s d effect size estimates reﬂect differences in HRQoL for each pairwise comparison. All p-values are signiﬁcant after Bonferroni-adjustment or Tukey’s HSD. ***p < .001; **p < .01; *p < .05.

reﬂect current physical and mental health as well as premorbid neurocognitive functioning. Furthermore, SA status
is associated with better every day functioning, supporting
the ecological validity of distinguishing SA from CN and CI
individuals.
Given the marked difference in average age between our
cohort of older PLWH and previous SA cohorts of healthy
elders, our SA criteria and study results cannot be directly
linked to the extant SA literature. However, there are several
strengths of our peak-age approach to deﬁning neurocognitive SA in the context of HIV infection. First, we do not focus
on one speciﬁc domain of neurocognitive functioning.
Instead, our SA criteria are deﬁned by absence of peak-age
impairment in global neurocognitive functioning and absence
of actual-age impairment in all domains assessed. PLWH are
a heterogeneous group whose neurocognition may be
impacted by HIV and demographic and clinical confounds,
contributing to a neurocognitive proﬁle that is not deﬁned by
deﬁcits in any one neurocognitive domain. Thus, we
demonstrate merit in deﬁning SA by global performance to
match what is known about neurocognitive functioning
among PLWH.
An important feature of our global estimates of neurocognitive functioning is that they are adjusted for practice
effects, as some study participants had prior exposure to the
neurocognitive testing battery. Practice, or learning, effects
complicate assessment of SA because seemingly elite neurocognition can be an artifact of prior testing experience. By
correcting for normal test–retest ﬂuctuations, we reduce the
likelihood of overestimating neurocognitive ability and
enhance the stringency of our SA criteria.
We compared neurocognitive functioning of our sample to
normative standards for age 25 when neurocognitive functioning is maximal (Salthouse, 2009). The concept of SA

(Rogalski et al., 2013) posits that, within an individual’s adult
life, aging does not necessitate neurocognitive decline.
Rather, aging increases the likelihood of encountering
adverse events that contribute to neuronal damage and
decline in neurocognition. Deﬁning SA in this way may
facilitate understanding of the kinds of events or experiences
that either support, or damage, neurocognitive functioning.
SA had lower rates of unemployment and IADL dependence than the other neurocognitive status groups and
higher self-reported physical and mental HRQoL. Thus, our
method for deﬁning SA appears to be concurrently valid
with measures of everyday functioning and HRQoL.
Importantly, CN and SA groups differ in real-world outcomes, indicating heterogeneity among neurocognitively
unimpaired individuals. Unlike prior investigations of SA,
our deﬁnition of SA did not require self-reported IADL
independence as a criterion. Despite performance-based
data indicating SA, a small proportion of the SA group
endorsed IADL dependence. Among our SA group, selfreported declines in IADL may represent actual decline,
such that SA individuals may have started at higher levels of
functioning and experienced a decline that is not necessarily
at an impaired level.
To this point, our measure of IADL dependence may be
overly sensitive in detecting decline and not speciﬁc in
detecting whether this decline represents a shift from within
normal functioning to impairment status. Given that most
other studies rely on absence of IADL dependence or decline
when deﬁning SA, these studies may be potentially misidentifying SA individuals who perform at peak-age levels on
neurocognitive tests. Thus, future investigations need to
consider the appropriate use of performance-based versus
self-reported deﬁcits when classifying individuals as SA
versus CN.
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Consistent with prior research, the WRAT reading subtest,
an estimate of premorbid verbal IQ that is relatively resistant
to HIV-associated neurocognitive decline (Casaletto et al.,
2014), was higher in SA and predicted SA status. Moore et al.
(2014) demonstrated a positive correlation between a composite measure of cognitive reserve, including verbal IQ, and
successful cognitive aging in older PLWH. The theory of
cognitive reserve postulates that effects of neural insults, such
as age and comorbidities, are buffered by robust brain networks (Stern, 2002). Although operational deﬁnitions and
methods of quantifying cognitive reserve may vary across
studies (Moore et al., 2014; Nucci, Mapelli, & Mondini,
2012; Reed et al., 2010; Selzam et al., 2017), cognitive
reserve is considered to reﬂect a combination of geneticallydriven intellectual capacity and cognitively stimulating life
experiences that promote resilience against age-related neurocognitive decline (Daffner, 2010; Stern, 2012).
Although SA displayed higher premorbid functioning on
the WRAT, neurocognitive status groups did not differ on
years of education. Thus, neuroprotective beneﬁts measured
by higher WRAT performance may be better explained by
factors other than education, such as genetically driven neurocognitive resilience. More granular methods of quantifying
both the genetic (e.g., polygenic risk scores) and environmental (e.g., educational quality, socioeconomic factors)
loadings of cognitive reserve are needed to thoroughly
address questions regarding premorbid functioning and agerelated neuroprotection.
Among HIV-uninfected individuals, diabetes is also
strongly associated with neurocognitive impairment and is
considered to be a predisposing factor for later development
of vascular dementia and Alzheimer’s disease (Cheng,
Huang, Deng, & Wang, 2012; Taguchi, 2009). Insulin
resistance and diabetes are associated with MRI structural
abnormalities and functional alterations of the blood brain
barrier, resulting in processes that facilitate the pathogenesis
and progression of neurocognitive impairment (Archibald
et al., 2014; Mogi & Horiuchi, 2011; Prasad, Sajja, Naik, &
Cucullo, 2014). We found a stair-step effect for the inﬂuence
of diabetes on neurocognitive status such that CI individuals
were characterized by the highest rates of diabetes, followed
by CN, and then SA participants; associations between diabetes and neurocognitive status remained in multivariable
analyses.
Other studies have found similar increases in risk for
HAND among HIV-infected persons with self-reported diabetes or elevated fasting insulin levels (McCutchan et al.,
2012; Valcour et al., 2006, 2005; Vance et al., 2014). Thus,
for SA participants, their relatively low incidence of diabetes
likely contributed to better neurocognitive functioning.
However, the effect of diabetes was not signiﬁcant when
restricting our multinomial regression analysis to virally
suppressed participants, underscoring the importance of other
contributing factors to SA status.
SA had lower BDI-II scores than both CN and CI univariately and in the multinomial logistic regression. In contrast, rates of current and lifetime MDD diagnoses did not

signiﬁcantly differ by neurocognitive status group, indicating
that among older PLWH, current subclinical depressive
symptoms are associated with neurocognitive functioning
more closely than active or remote clinical depression. This
relationship may reﬂect known neurological consequences of
depression, including neuroinﬂammation and associated
neuronal damage, apoptosis, and reduced neurogenesis
(Kubera, Obuchowicz, Goehler, Brzeszcz, & Maes, 2011;
Maes et al., 2009). Behavioral mechanisms may also underlie
the relationship between depression and neurocognition, as
depressive symptoms (even those that are subclinical) negatively impact engagement in activities known to promote
neurocognitive health, including exercise, healthy nutrition,
and social activity (Jeste, Depp, & Vahia, 2010; Moore et al.,
2018; Vahia et al., 2010).
SA displayed greater rates of lifetime cannabis use disorder in comparison to CI, and this pattern also remained
signiﬁcant in the multinomial logistic regression. This result
is supported by evidence suggesting neuroprotective effects
of cannabis use through activation of cannabinoid receptors
(i.e., CB1 and CB2) in the central nervous system (Sanchez &
Garcia-Merino, 2012). Speciﬁcally, CB1 agonists reduce
excitotoxity in post-synaptic neurons (Marsicano et al., 2003)
while CB2 agonists promote anti-inﬂammatory and immunomodulatory actions (Rom & Persidsky, 2013).
Nevertheless, the relationship between cannabis use and
brain integrity among PLWH and HIV-uninfected adults
remains a controversial matter. While chronic cannabis use
has been associated with neurometabolic abnormalities,
reduced gray matter volumes, and memory deﬁcits in cohorts
comprised of PLWH and seronegative controls (Battistella
et al., 2014; Chang, Cloak, Yakupov, & Ernst, 2006;
Cristiani, Pukay-Martin, & Bornstein, 2004; Thames et al.,
2017), emerging evidence suggests that active cannabis use
may limit HIV viral replication and attenuate HIV-related
immunosuppression, inﬂammation, and cerebral glutamate
depletion (Chang et al., 2006; Rizzo et al., 2018; Thames,
Mahmood, Burggren, Karimian, & Kuhn, 2016). These
neuroprotective properties of the cannabinoid system are not
referenced in the context of a cannabis use disorder, which
may reﬂect problematic use or heavy exposure that could
exceed therapeutic levels.
Moreover, prior studies examining elite neurocognition in
healthy elders have excluded participants with substance use
histories that could inﬂuence neurocognition. Thus, our
cannabis-related ﬁndings cannot be compared to prior SA
studies and the relationship between cannabis use disorder
and neuroprotection in HIV remains poorly characterized.
Future research is needed to explore therapeutic levels of
cannabis use and identify potential beneﬁts of cannabinoid
receptor activation on neurocognition among PLWH.
Despite stair-step patterns for HIV disease characteristics
in SA individuals compared to CN and CI participants, only
the proportion of participants with current CD4 counts below
200 was statistically signiﬁcantly different among the neurocognitive status groups. Speciﬁcally, the SA group had a
lower proportion with current CD4 counts below 200 than the
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CI group. However, this difference was not statistically signiﬁcant when controlling for other clinical and demographic
variables (e.g., age, WRAT, and depressive symptoms).
Unexpectedly, the SA and CN groups had low nadir CD4
counts comparable to the CI group, possibly reﬂecting
underlying resilience to the “legacy” effects of advanced
immunosuppression.
In a comparison of predictors of HAND before and during
the era of ART, only low nadir CD4 was found to increase
risk of neurocognitive impairment in both treatment eras
(Heaton et al., 2011). However, when examining factors
associated with decline to symptomatic HAND, current CD4
also predicted decline to symptomatic status (Grant et al.,
2014). SA with current CD4 counts below 200 were more
likely to be off ART. Furthermore, the higher proportion of
participants with CD4 counts below 200 in the CI group may
result from poorer ART adherence that is a consequence of
their cognitive impairment. Given that the majority of participants were likely to begin ART after having advanced HIV,
it is unclear whether similar relationships between HIV disease severity and neurocognitive status exist for modern era
patients who typically start treatment at earlier stages.
The observation that SA prevalence was twice as high in
HIV-uninfected comparison participants as compared to
PLWH provides important context to our ﬁndings. This difference, in addition to the higher prevalence of CN and lower
prevalence of CI in HIV-uninfected controls, aligns with the
known independent neurotoxic effects of HIV and potential
synergistic effects of aging with HIV. Compared to their
seronegative counterparts, older PLWH must withstand a
greater amount of exposure to neural insults to sustain an elite
level of neurocognitive performance. It is important to note
that the HIV-uninfected group was demographically distinct
from the PLWH group, as indicated by a higher prevalence of
non-Hispanic whites, more years of education, and better
WRAT Reading scores. Thus, the estimated two-fold difference in SA prevalence may be partially confounded by
potential socio-demographic advantages of the HIVuninfected group.
Several limitations to the present study warrant discussion.
Our peak-age corrected neurocognitive scores, based on a
normative sample of 25-year-olds, serve as proxy measures
for neurocognitive resilience and do not directly capture the
true within-subject change in neurocognitive performance
since age 25. Because our data are cross-sectional, we cannot
rule out the possibility that members of the SA group have
experienced considerable lifetime neurocognitive decline and
that their SA status is an artifact of superior baseline neurocognitive capacity. Although our analysis demonstrating that
older age was associated with lower global scaled scores in
CN and CI groups, but not the SA group, preliminarily supports the validity of our SA criteria, the magnitude of these
age effects were small and did not signiﬁcantly differ across
groups. In addition to other factors importantly contributing
to variance in global neurocognitive performance, these small
effect sizes are likely inﬂuenced by the narrow age range of
our sample.

R. Saloner et al.
Our results highlight clinically informative predictors and
beneﬁts of neurocognitive resilience; yet, the racial/ethnic
composition of our sample was predominantly non-Hispanic
white men and may limit the generalizability of our ﬁndings
to more socio-demographically diverse populations. Furthermore, our cohort of older PLWH is relatively young
compared to the healthy adult cohorts studied in the extant
SA literature of persons not living with HIV, but the age
range is indicative of some of the oldest PLWH with a sufﬁcient sample size to be studied. Although the inclusion of an
age-matched HIV-uninfected comparison group provided an
informative anchor point for SA prevalence in healthy adults,
this comparison group was not comparable to the PLWH
group on other important demographic factors. Consequently, important questions remain regarding the extent to
which our deﬁnition of SA in PLWH reﬂects resilience to the
effects of HIV and aging into late adulthood, which may only
be adequately addressed with data from ideal comparison
groups. As the proportion of PLWH older than 65 years of
age increases, longitudinal cohort studies of PLWH will be
better equipped to address critical questions related to the
prevalence, stability, and impact of SA in PLWH compared
to healthy seniors.
Although we focused on evaluating the relationships
between SA status and clinical correlates commonly assessed
in PLWH, the absence of biomarker data indicative of central
nervous system integrity (e.g., neuroimaging, cerebrospinal
ﬂuid assays) prevents us from determining the neurobiological correlates of SA status. Additionally, an assessment of
modiﬁable behaviors (e.g., physical activity, neurocognitive
activity, positive psychological outlook) that may mediate
the relationships between SA status and psychosocial, medical, and everyday functioning correlates could help to
prioritize research in clinical interventions to increase the
fraction of SA in PLWH (Vance & Burrage, 2006).
Taken together, our results demonstrate that a substantial
fraction of older, HIV-infected patients maintain their maximal neurocognitive abilities that confer real-world beneﬁts
even compared to patients with normal age-related cognitive
decline. Although HIV disease negatively impacts the prevalence of SA, our ﬁndings highlight the clinical value in
identifying neurocognitive resilience within PLWH and
focus on the potential for positive outcomes despite aging
with HIV. Examination of the stability of SA status through
longitudinal analysis, exploration of biological and genetic
markers of neuronal integrity, and assessment of modiﬁable
lifestyle factors should enhance studies of future interventions to improve neurocognitive aging in older PLWH.
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